Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced its financial results for the fiscal fourth quarter and full year ended June 30, 2025.
The company achieved sequential and year-on-year revenue growth of 16%, driven by increased demand for drug testing cartridges and operational efficiencies.
Key highlights include progress towards securing FDA 510(k) clearance for U.S. market expansion beyond Forensic Use Only settings.
Revenue Growth
16% revenue growth in fiscal Q4, supported by increased cartridge sales.
Regulatory Advancements
Focused efforts on securing FDA 510(k) clearance for opiate test system in the U.S.
Market Expansion
Active customer base exceeding 450 accounts across 24 countries with 18 distribution partners.
- Progress on FDA clearance pathway for U.S. market expansion.
- Revenue from cartridge sales increased significantly, contributing to higher-margin revenue stream.
- Expansion into key markets with revenue growth across various sectors and geographies.
Intelligent Bio Solutions Inc. shows strong growth momentum driven by revenue increases and operational efficiencies. The focus on FDA clearance and market expansion positions the company for continued success in the medical technology sector.